“The study reveals that women who experience early menopause (before age 40) have an increased risk of developing breast and ovarian cancer," she says. "These women face double the risk for breast cancer and nearly four times the risk for ovarian cancer compared to those who undergo menopause at a typical age. “Given these findings, for those women who undergo early menopause and those having fertility issues due to early menopause or low egg numbers, need to have regular cancer screenings, especially if there is a family history of cancer."
AOA Dx
Biotechnology Research
Denver, CO 6,799 followers
Revolutionizing early diagnosis of Ovarian Cancer
About us
AOA Dx is developing the next frontier in early-stage cancer detection for women through its pioneering work in glycolipids and proprietary biomarker technology. Our revolutionary tumor marker ganglioside platform, GlycoLocate™, is paving the way for life-saving early cancer detection. In a first of its kind, AOA Dx is developing AKRIVIS GD™, an early-stage liquid biopsy test for ovarian cancer, that has proven excellent sensitivity and specificity in a recent study. We foresee novel tumor biomarker gangliosides as the future for diagnosis, prognosis, monitoring, and eventually targeted therapies across multiple cancers. AOA Dx was co-founded by three experts and passionate advocates of women’s health, who have worked together at two previous diagnostic startups, that both resulted in successful exits upon commercialization. AOA Dx, a Y combinator and VC backed company, raised an oversubscribed Seed Round to accelerate development and clinical studies. Awards & Accelerators: 1. Y Combinator 2. MassChallenge 3. Springboard Enterprises 4. MassMedic Ignite 5. Inc Magazine Top 100 Female Founders 6. Women's Health Innovation Summit Award 7. Massachusetts Life Sciences Center MassNextGen Award 8. The Wave Summit's Emerging Women Founder in Bio Award 9. The Eddies Award 10. Bloomberg New Economy Catalyst www.aoadx.com
- Website
-
http://www.aoadx.com
External link for AOA Dx
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Denver, CO
- Type
- Privately Held
- Founded
- 2020
- Specialties
- Medical Devices, Diagnostics, Prognostics, Biotechnology, Sales, Commercialization, Regulatory, Licensing, Quality, FDA, IVD, CE IVDR, Ovarian Cancer, Women's Health, Cancer Diagnostics, and Liquid Biopsy
Locations
-
Primary
Denver, CO 80221, US
-
New York City, NY 10011, US
-
Cambridge, MA 02138, US
Employees at AOA Dx
-
Anthony Bajoras
Managing Director at CANCER FUND
-
Sharon Vosmek
CEO, Astia & Managing Partner, Astia Fund. Series A/B Investor, Board Member, Advisor, Speaker, fierce advocate for her portfolio
-
Alice Zheng
Principal at RH Capital | women's health expert | MD/MBA/MPH | ex-McKinsey
-
Abigail McElhinny
Experienced product development executive
Updates
-
Congratulations to our CEO & Co-Founder Oriana Papin-Zoghbi for winning the People's Choice Award for the AIM-HI Accelerator Fund! We greatly appreciate everyone who took the time to cast their vote and show support for the work we are doing at AOA Dx!!
🎊 The 2024 Women’s Venture Competition launched the “People's Choice for Best Pitch” voting campaign, inviting the public audience to participate and vote for their favorite pitch from our seven semi-finalists. We are excited to announce that the “People's Choice for Best Pitch” goes to Oriana Papin-Zoghbi, CEO & Co-Founder of AOA Dx! Her compelling presentation introduced AOA’s groundbreaking novel technology for the early diagnosis of ovarian cancer, raising awareness about the importance of early cancer detection through the use of biomarkers. Congratulations to Oriana and the AOA team! Who will be the top finalists selected by the 2024 Women’s Venture Competition judging committee? Stay tuned to find out! https://lnkd.in/duHNVZQx #AIMHIaccelerator #WomensVentureCompetition #EmpoweringWomenInOncology #EmpoweringWomenEntrepreneurs #EarlyCancerDetection #OvarianCancer
-
Last week our Co-Founder & COO Alexander Fisher spoke at the Mountain West BioLife Summits in Denver to promote Colorado as a future hub of biotech! Moderator: Elyse Blazevich, President & CEO, Colorado BioScience Association, President, Colorado Bioscience Institute Panelists: Isaac Foster, CEO, Endourage Julie Stiff, Interim Site Head & Sr Director Facilities & Engineering, Boulder Operations, KBI Biopharma Erin Fosdick, President & CEO, Longmont Economic Development Partnership
-
We are excited to introduce you to Charles M. Nichols, Ph.D., our new Mass Spectrometry Scientist! Charles is a bioanalytical chemist that specializes in LCMS method development and validation. At AOA Dx, he works with developing assay platforms using HPLC-FC-ELSD and LC-HRMS/MS. Welcome Charles, we're thrilled to have you on board 👏 !
-
AOA is thrilled to be part of the American Cancer Society's Fork Cancer event on July 18, 2024, at Mile High Station in Denver! Come enjoy Denver's finest culinary delights, drinks, and live entertainment with us, all while supporting a great cause. We're excited to participate this year because the American Cancer Society is focusing on increasing access and funding for biomarker testing in 2024. This is crucial for our test's market introduction and ensuring insurance covers its cost. Our GlycoLocate™ platform will be the first of its kind to use tumor marker gangliosides as biomarkers to diagnose early-stage cancers by using a non-invasive blood test. Join us in this important mission and help us reach our goal of $5,000! Learn more here: https://lnkd.in/dKGBVFSs
-
"Early detection improves treatment outcomes for endometrial and ovarian cancers, yet far too often women are diagnosed in advanced stages of these diseases. Unlike many other cancers, there are no standard screenings for early detection of endometrial and ovarian cancers. The incidence rate for endometrial cancer is expected to rise, driven by environmental factors, obesity and diabetes."
Mayo Clinic researchers uncover microbial signatures linked to gynecologic cancers
news-medical.net
-
Warm welcome to our Chief of Staff Emma Martin!!! Emma is a mission-driven operator who is passionate about improving processes and culture within a leadership team and organization in order for everyone to work more effectively. She began her career as the fourth hire at a healthcare startup, where she played a pivotal role in establishing and developing the company's sales organization, and sold to Fortune 500 health plans. Her exceptional leadership and strategic acumen led to taking on the role as Chief of Staff, where she continued to drive organizational efficiency and support executive decision-making. Emma's unique blend of scientific knowledge and business expertise enables her to navigate the complexities of the healthcare industry effectively. Welcome Emma! We're so excited to have you on our team! 👏
-
AOA Dx is currently participating in the AIM-HI Accelerator Fund Women's Venture Competition, an annual competition that provides funding for women entrepreneurs in oncology. AOA was selected as one of 4 finalists and recently completed the final pitch in front of a panel of judges. In addition to the competition winner, AIM-HI is also selecting the "People's Choice Award" for the pitch that receives the most votes from the public. If you have a few spare minutes before this Friday, I would appreciate it if you went to the below link and vote for AOA's pitch. https://lnkd.in/eDrpZveg Thank you!
Vote for our CEO + Co-Founder Oriana Papin-Zoghbi for the 2024 AIM-HI Accelerator Fund Women's Venture Competition!!! The annual AIM-HI Women’s Venture Competition provides critical funding for women entrepreneurs in oncology. As we know, there is so much work that needs to be done to improve outcomes for women with gynecological cancers. This financing helps to bring next-generation therapeutics, diagnostics, and prevention technologies to patients. Vote now!!! 🎉
2024 Women's Venture Competition - People's Choice Award - AIM-HI
https://aim-hiaccelerator.org
-
We are so proud to be featured as a change maker in the Springboard Enterprises x Accenture "State of Women's Health" report! https://lnkd.in/eKA5cUPg, It is such an honor to be recognized for our work with ovarian cancer, women's health, and more. The "State of Women’s Health" report dives into the current state of women’s health, highlighting key areas where innovation and funding is urgently needed. Traditionally, this field has faced challenges such as limited funding, inadequate research, and pervasive misconceptions. A considerable gap in public awareness and response persists. This report aims to close this gap by increasing awareness, motivating action, and promoting advancements in funding, research, and innovation. Join us in amplifying this report and driving continued change! 👏
-
AOA Dx reposted this
It’s #EqualResearchDay! 💥 Evvy created #EqualResearchDay on June 10 because women weren’t required in U.S. clinical research until June 10th, 1993 (Think Equal Pay Day but for the gender health gap!) To this day, there are countless holes ⚫ in our scientific and medical understanding of the female body — and that directly impacts us as patients. If you’ve ever experienced delays in diagnoses, failed treatments, mystery symptoms with no answers, or medical gaslighting — #EqualResearchDay is for you. This year, we brought together 46 innovative companies and compiled 100 Effed Facts about the Gender Health Gap across 12 health areas: ⚫ Autoimmune Disease ⚫ Brain + Mental Health ⚫ Cancer ⚫ Endometriosis ⚫ Fertility ⚫ Heart Health ⚫ Hormonal Health ⚫ Maternal Health ⚫ Medical Gaslighting ⚫ Menopause ⚫ Menstrual & Sexual Health ⚫ Vaginal & Urinary Health Earlier this week, we launched a limited-edition coffee table book featuring all 100 Effed Facts to benefit Women's Health Access Matters (you can order a copy at EqualResearchDay.com before they sell out... !) But we decided these facts are too important not to share widely — so we are posting a public version here on LinkedIn. 𝗛𝗢𝗪 𝗬𝗢𝗨 𝗖𝗔𝗡 𝗛𝗘𝗟𝗣: 💥 Share this post (and add your story about why equal research matters to you)! 💥 Learn more and shop the limited edition coffee table book to benefit WHAM at EqualResearchDay.com The female body shouldn’t be a medical mystery — together, let’s close the gender health gap for good. #equalresearchday2024 #evvy #genderhealthgap #closethegenderhealthgap ——— 2024 Equal Research Day Collaborative: Evvy Aavia adyn Allara AOA Dx Bloomer Tech Caraway Clue Cofertility Conceive Diem DotLab Doveras Elektra Health Elix Frame Gabbi Gaia Gameto Health In Her HUE HerMD Hey Jane The Honey Pot Company Iron Health Julie Products Inc. Live UTI Free Looni Love Wellness Midi Health Millie Neura Health Origin Oova Poppy Seed Health Paloma Health Rescripted Rosy Wellness Ruth Health (YC S21) Seven Starling Stripes Sunfish Teal Health Thirty Madison TMRW Vella Bioscience Veracity WellTheory